Navigation Links
CV Therapeutics Reports 2008 Second Quarter Financial Results
Date:7/31/2008

arges - 5,367 - 5,367

Net loss, non-GAAP $(4,294) $(39,045) $(36,193) $(94,101)

Basic and diluted net loss

per share, as reported $(0.07) $(0.97) $(0.60) $(1.91)

Adjustments $- $0.31 $- $0.31

Basic and diluted net loss

per share, non-GAAP** $(0.07) $(0.66) $(0.60) $(1.59)

Shares used in computing

basic and diluted net loss

per share 60,856 59,223 60,706 59,089

**The values shown above are exact; totals may not appear to sum due to rounding

CONSOLIDATED BALANCE SHEET DATA

(In Thousands)

(Unaudited)

June 30, 2008 December 31, 2007

Assets:

Cash, cash equivalents, and

marketable securities $272,313 $174,245

Other current assets 40,874 41,825

Total current assets 313,187 216,070

Property and equipment, net 16,639 19,131

Other assets 20,815 23,635

Total assets $350,641 $258,836

Liabilities and stockholders' deficit:

Current liabilities $46,534 $39,183

Convertible subordinated notes 346,500 399,500

Deferred revenue 159,805 -

Other long-term obligations 4,675 5,551

Stockholders' deficit (206,873) (185,398)

Total liabilities and stockholders'

deficit $350,641 $258,836


'/>"/>
SOURCE CV Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
3. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
4. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
5. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
6. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
9. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
10. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... pet owners drew up their lists of New Year,s resolutions for ... of my furry companion." Nowadays there are pet salons, dog and ... take the little canine or feline darlings along wherever mommy or ... pricey toys at the pet store. But anyone who has ever ...
(Date:1/14/2014)... and BETHESDA, Md. , Jan. ... together with two institutes from the National Institutes of ... for bringing safer, more effective treatments to patients on ... Center for Advancing Translational Sciences (NCATS) and the National ...
(Date:1/14/2014)... , Jan. 14, 2014  RXi Pharmaceuticals Corporation ... developing and commercializing innovative therapies addressing major unmet ... it received the Notice of Allowance from the ... unique self-delivering RNAi compounds (sd-rxRNA®), for the treatment ...
(Date:1/14/2014)... Bellingham, Washington, USA, and Cardiff, UK (PRWEB) January 13, ... and photonics technology development leader with more than 20 ... international society for optics and photonics . Hainsey will ... “We are delighted to have Dr. Hainsey join SPIE ...
Breaking Biology Technology:New Year's Resolution: Give Pets the Gift of Top-Notch Health Care 2Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3Photonics R&D Leader Bob Hainsey Joins SPIE Technical Staff 2
... has announced an exclusive contract with Trek Bicycle Corporation ... and Leum Software intend to enhance the current Ascend software ... help them manage their business with increased efficiency. , ,We ... successful. In the future, a dealers success will depend more ...
... effort to gather a burgeoning number of stem cell ... the University of Wisconsin-Madison has established the new Wisconsin ... of the UW-Madison Graduate School, the new initiative is ... efforts to develop new resources and opportunities for as ...
... Companies that do not specialize in software, but incorporate ... products, more often than not, overlook the importance of ... biggest feature or the most prevalent feature of the ... can and should be protected. , ,For example, ...
Cached Biology Technology:UW Madison launches new stem cell research program 2Beyond the screws and gears: Protecting your products by protecting your software 2
(Date:4/17/2014)... inhibits RSV infection , Respiratory syncytial virus ... tract infections, generating life-threating illness in very young ... are limited. RSV enters host cells through the ... fusogenic bundle. Small interfering peptides that prevent bundle ... peptides are highly susceptible to degradation. In this ...
(Date:4/17/2014)... Gauthier and Professor Luca Razzari of the nergie ... large grants from the John R. Evans Leaders ... for the acquisition of state-of-the-art biotech and nanophotonics ... grants from the Ministre de l,Enseignement suprieur, de ... Technologie (MESRST). These new laboratories will help us ...
(Date:4/17/2014)... produce hydrogen sulfide in order to properly multiply and ... the Center for Craniofacial Molecular Biology at the Herman ... Shi, principal investigator on the project, said the presence ... flow of calcium ions. The essential ions activate a ... the creation of new bone tissue, and keeps the ...
Breaking Biology News(10 mins):JCI online ahead of print table of contents for April 17, 2014 2JCI online ahead of print table of contents for April 17, 2014 3JCI online ahead of print table of contents for April 17, 2014 4JCI online ahead of print table of contents for April 17, 2014 5JCI online ahead of print table of contents for April 17, 2014 6New state-of-the-art biotech and nanotech equipment for INRS 2
... one of the first efforts of its kind, UCLA researchers have ... showing not just the order in which genes fall in the ... findings, published in the August issue of the journal Genome ... and shed light on how they collaborate to help cells thrive ...
... mortality worldwide, accounting for more than one in ten deaths. ... million. The ESMO Congress provides a major international forum for ... Congress Program Highlights , , New ... new drugs to treat ovarian, skin, colorectal and other cancers, ...
... world is diagnosed with breast cancer every 23 seconds. It ... and approximately 456,000 die from the disease each year. At ... a scientist is taking aim at the molecular machinery behind ... G. Komen for the Cure, Catherine Denicourt, Ph.D., an assistant ...
Cached Biology News:UCLA scientists map all mammalian gene interactions 2UCLA scientists map all mammalian gene interactions 335th ESMO Congress media alert 235th ESMO Congress media alert 3
6X DNA Gel Loading Buffer is intended for gel electrophoresis of DNA fragments or PCR products....
Makes gels easy to load and track during electrophoresis. 10X concentrate of Bromophenol Blue, Xylene Cyanol, glycerol solution in TE...
Agarose Gel Loading Dye Mixture 6X...
Pharmalyte, narrow range pH 4.2-4.9, 25 ml. Category: Electrophoresis Systems & Standards & Reagents, Electrophoresis Standards and Reagents, Immobiline for IEF and Carrier Ampholytes....
Biology Products: